The shareholders of JHL Biotech voted to approve the company’s voluntary delisting from the Taiwan stock exchange.
February 2, 2018 -- The shareholders of JHL Biotech voted to approve the company’s voluntary delisting from the Taiwan stock exchange. The biosimilar company, which has a $419 million market capitalization, operates in Taiwan and Wuhan, China. Unlike most privatizations, the voluntary transaction does not require shareholders to tender their shares in the company, nor does it involve private equity/loan backing. JHL says the transaction allows the company to seek new sources of financing, including a foreign IPO -- which could be in Hong Kong.
